Sign In
Buy JNJ
$244.88
+3.88 (+1.61%)
At Close: Jun 25, 2026
Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts
06:51pm, Wednesday, 21'st Feb 2024
In the most recent trading session, Johnson & Johnson (JNJ) closed at $158.68, indicating a +0.52% shift from the previous trading day.
5 Safe Dividend Aristocrats To Buy Now – Huge Wall Street Sell-Off Could Be Coming
11:50am, Wednesday, 21'st Feb 2024
Top financial advisors are now accepting new clients for 2024! Finding the right advisor can be the difference between retiring early, or working forever.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
10:05am, Wednesday, 21'st Feb 2024
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bi-weekly dose of Johnson & Johnson's blood cancer therapy gets US FDA approval
04:42pm, Tuesday, 20'th Feb 2024
The U.S. Food and Drug Administration has approved a bi-weekly dose of the blood cancer therapy Tecvayli, Johnson & Johnson said on Tuesday.
Top 7 Contenders to Join the Trillion-Dollar Club
01:54pm, Tuesday, 20'th Feb 2024
By hitting the elusive $3 trillion mark in valuation last month, Microsoft (NASDAQ: MSFT ) reignited the debate over trillion-dollar companies. This monumental achievement, fueled by the burgeoning
Income Lover's Paradise: 3 Dividend Stocks with Stellar Track Records
06:25am, Tuesday, 20'th Feb 2024
Dividend stocks not only offer the potential for capital appreciation but also provide a steady income stream. According to S&P Dow Jones Indices research, dividends have contributed about 32% of the
Steady Eddies: 3 Blue-Chip Stocks to Buy for the Long Haul
01:49pm, Sunday, 18'th Feb 2024
Blue-chip stocks refer to stocks of large, well-established companies with a reputation for high-quality, reliable investments. They tend to be industry leaders in their sectors and have a large marke
# Dividend Stocks Charlie Munger Would Have Loved
08:10am, Sunday, 18'th Feb 2024
Click this if you want to hear 5 Warren Buffett Dividend Stocks to Grab Now Before Recession Cracks the Market URGENT – New Seats Available (sponsored) Top financial advisors are now accepting new c
3 Unstoppable Dividend Stocks That Could Pay You for Life
09:51am, Saturday, 17'th Feb 2024
Johnson & Johnson has an incredible streak of annual dividend raises. Apple's booming services segment and vast ecosystem are the future of the business.
Alvotech settles with J&J to launch Stelara biosimilar in Europe, Canada
07:00am, Thursday, 15'th Feb 2024
Alvotech said on Thursday it has reached settlement agreements with Johnson & Johnson for launching the biosimilar of the pharmaceutical giant's blockbuster psoriasis drug Stelara in Japan, Canada and
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
04:30pm, Wednesday, 14'th Feb 2024
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at the Loews Miami Beach Hotel,
7 Stable Dividend Stocks to Ease Lingering Market Jitters
02:13pm, Tuesday, 13'th Feb 2024
Easily one of the top talking points of last year is that with the economy avoiding a recession, mitigation protocols – such as targeting stable dividend stocks – seem rather unnecessary. Neverthe
3 Dow Stocks You Can Confidently Buy Now and Hold Forever
05:21am, Tuesday, 13'th Feb 2024
The Dow Jones Industrial Average has been Wall Street's health barometer since the late 1800s. The Dow comprises 30 time-tested, multinational businesses, which means it's a great place for investors
A Look at Pharma ETFs After Q4 Earnings
02:01pm, Monday, 12'th Feb 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs re
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
07:30am, Monday, 12'th Feb 2024
The healthcare industry can be a relatively stable place to invest for generating long-term wealth. AbbVie is dealing with the blow of losing Humira patent exclusivity, but there's more behind the bus
